Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01908192
Recruitment Status : Recruiting
First Posted : July 25, 2013
Last Update Posted : September 13, 2021
Sponsor:
Information provided by (Responsible Party):
SyneuRx International (Taiwan) Corp

Brief Summary:
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: NaBen® Drug: Placebo Phase 2 Phase 3

Detailed Description:

This is a two-part, multi-center, prospective, randomized, placebo-controlled, parallel-group study, in which adolescent subjects with schizophrenia will be enrolled. Overall, eligible subjects will be randomized in a pre-defined 1:1 ratio to NaBen® or placebo.

This study will be conducted in two parts:

In Part 1 (Phase IIb) of the study, 76 subjects (~ 60% of the total planned subjects) will be randomized in a 1:1 ratio (NaBen® or placebo), of which 38 subjects will be randomized to the NaBen® group and 38 subjects to the placebo group. An interim analysis (IA) will be conducted after the randomization of the 76th subject in Part 1 of the study. The data will be analyzed after all enrolled subjects in Part 1 of the study complete Visit 5 (week 6) or are withdrawn from the study, whichever occurs first. The data from IA will be reviewed by an independent Data Safety and Monitoring Committee (DSMC) that will be responsible for the review of the data from the Part 1 (Phase IIb) of the study for both safety and the effectiveness.

In Part 2 (Phase III) of the study, a total of 50 subjects will be randomized, of which 25 subjects will be randomized to the NaBen® group and 25 subjects to the placebo group. The final subject numbers in the study will depend on the sample size re-estimation after Part 1 of the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 126 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents
Study Start Date : June 2014
Estimated Primary Completion Date : June 30, 2023
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: NaBen®
NaBen® is a white oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
Drug: NaBen®
The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo).

Placebo Comparator: Placebo
The control treatment is placebo.
Drug: Placebo
The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient.




Primary Outcome Measures :
  1. Mean change from baseline in Positive and Negative Syndrome Scale (PANSS) total score after 6 weeks of treatment [ Time Frame: Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6. ]

Secondary Outcome Measures :
  1. Percent change from baseline in Positive and Negative Syndrome Scale (PANSS) total score from baseline after 6 weeks of treatment [ Time Frame: Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6. ]
  2. Percentage of subjects with 20% or more reduction in Positive and Negative Syndrome Scale (PANSS) total score from baseline after six (6) weeks of treatment [ Time Frame: Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6 ]
  3. Percent change in Positive and Negative Syndrome Scale (PANSS) sub-scales [ Time Frame: Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6. ]
  4. Percent change in Scale for Assessment of Negative Symptoms (SANS) total scores [ Time Frame: Scale for Assessment of Negative Symptoms will be assessed at Visit 1 (Screening), Visit 3,4,5, and 6 ]
  5. Percent change in Scale for Assessment of Negative Symptoms (SANS) sub-scale scores [ Time Frame: Scale for Assessment of Negative Symptoms will be assessed at Visit 1 (Screening), Visit 3,4,5, and 6 ]
  6. Percent change from baseline in the PANSS total score after 6 weeks of treatment [ Time Frame: Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6 ]

Other Outcome Measures:
  1. Percent change in Children's Global Assessment Scale (CGAS) [ Time Frame: Children's Global Assessment Scale will be assessed at Visit 1(Screening), Visit 3, 4, 5, and 6 ]
  2. Percent change in Clinical Global Impression-Severity (CGI-S) [ Time Frame: Clinical Global Impression will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6 ]
  3. Percent change in Children's Depression Rating Scale-Revised (CDRS-R) [ Time Frame: Children's Depression Rating Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects who are between 12 and 17 years of age inclusive
  • Physician confirmed DSM-IV or -V diagnosis of schizophrenia based on MINI International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders Studies for Children and Adolescents, version 6.0 (MINI-KID, Version 6.0)
  • Are clinically stable with residual symptoms, defined as a total score of ≥ 60 of PANSS and a score of ≥ 40 for SANS
  • An unchanged antipsychotic medication regimen for at least eight (8) weeks prior to randomization into the study and expected to remain unchanged during the study (longer for depot or long-acting antipsychotics: ten (10) months for Aripiprazole (Maintena®) and Paliperidone (Xeplion®); six (6) months for Olanzapine pamoate monohydrate (Zypadhera®); and at least 6 times duration of the reported half life or minimum four (4) months for other depot or long-acting antipsychotics)
  • In good general physical health and all physical exam, neurological exam and laboratory assessments (urine/blood routine, biochemical tests and ECG) are clinically unremarkable per the investigator
  • Subject has a negative urine illicit drug screening test
  • Subject understands and is willing to sign the Informed Assent Form (IAF) prior to study entry and agrees to be available for all the study visits
  • The subject's guardian understands and is willing to sign the Informed Consent Form (ICF) prior to study entry and agrees to be available for all the study visits
  • Must not be a danger to self or others and must have family support available to be maintained as outpatients

Exclusion Criteria:

  • Meets the DSM-IV or -V criteria at screening for mental retardation, dissociative disorder, bipolar disorder, major depressive disorder, schizoaffective disorder, schizophreniform disorder, autistic disorder, or primary substance induced psychotic disorder. Other comorbid disorders; e.g., attention-deficit hyperactivity disorder (ADHD), are allowed as long as schizophrenia is the primary diagnosis and the comorbid disorder(s) do not require medication.
  • Subjects whose illness was resistant to antipsychotics according to prior trials of two different antipsychotics of adequate dose
  • History of epilepsy, head trauma, or neurological illness other than Tourette's syndrome
  • History of allergic reaction to sodium benzoate
  • Serious medical illnesses such as acute or chronic renal disease, liver failure or heart disease that, in the opinion of the investigator, may interfere with the conduct of the study.
  • Current substance abuse or positive urine illicit drug screening or history of substance dependence (including alcohol, but excluding nicotine and caffeine) in the past three (3) months.
  • Use of depot antipsychotics in the past six (6) months
  • Inability to follow protocol
  • Body Mass Index (BMI) > 35
  • Female subjects who are pregnant (as confirmed by urine pregnancy test performed at screening Visit) or are nursing, or who do not agree to abstinence or birth control during the study
  • Cancer within the last three (3) years except for basal cell carcinoma and squamous cell carcinoma
  • Previous participation in an intervention trial within 30 days of randomization
  • Subjects whose PANSS score has decreased more than 10 percent during the Screening Phase

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01908192


Contacts
Layout table for location contacts
Contact: Yashar Salek, MD 1-301-956-2527 yashars@amarexcro.com
Contact: Anand Balasubramanian, B Pharm. 1-301-956-2531 anandb@amarexcro.com

Locations
Show Show 23 study locations
Sponsors and Collaborators
SyneuRx International (Taiwan) Corp
Investigators
Layout table for investigator information
Principal Investigator: Robert Findling, MD Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Additional Information:
Layout table for additonal information
Responsible Party: SyneuRx International (Taiwan) Corp
ClinicalTrials.gov Identifier: NCT01908192    
Other Study ID Numbers: SNR-01-NaBen
First Posted: July 25, 2013    Key Record Dates
Last Update Posted: September 13, 2021
Last Verified: September 2021
Keywords provided by SyneuRx International (Taiwan) Corp:
Sodium Benzoate
Schizophrenia
Adolescent
Antipsychotic
Anti-psychotic
NMDA
NaBen
pediatric
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders